Cytoprotective And Supportive Care Agents
The decision to discontinue Sandostatin 200mcg and 1000mcg is not due to manufacturing, product quality, safety, or efficacy concerns, according to the Company.
Cumberland announced the relaunch of Ethyol (amifostine) for Injection indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, and to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.
The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).
The FDA has approved Wellstat Therapeutics' Vistogard (uridine triacetate) oral granules, the first treatment for patients following an overdose of 5-fluorouracil (5-FU) or capecitabine,
Lexicon announced top-line results from the Phase 3 study, TELESTAR, which evaluated oral telotristat etiprate in cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care.
The Food and Drug Administration (FDA) has issued a warning that pulmonary hypertension has been reported in infants and newborns treated with Proglycem (diazoxide; Teva) for low blood glucose.
Cannabis and cannabinoid pharmaceuticals can be helpful for nausea and vomiting, pain, and weight loss associated with cancer.
Amgen announced that the Food and Drug Administration (FDA) has approved Xgeva (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.
The Food and Drug Administration (FDA) has approved Akynzeo (netupitant and palonosetron; Eisai) to treat nausea and vomiting in patients undergoing cancer chemotherapy.
Tesaro has submitted a New Drug Application (NDA) to the FDA for approval of oral rolapitant for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Merck announced results from a Phase 3 Emend (aprepitant) study in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.
A medical practice in KY has pleaded guilty to federal charges regarding the purchasing and selling of unapproved and improperly labeled chemotherapy drugs.
Experts have identified three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients. The cost-cutting proposals call for changes in routine clinical practice involved in end-of-life care, medical imaging, and drug pricing.
The USPSTF has found that insufficient evidence to evaluate the benefits and harms of multivitamins and most single- or paired-nutrient supplements for the prevention of cardiovascular disease and cancer.
Recommendations relating to the key elements of minimum adequate cancer family history are detailed, although they are often incompletely implemented.
A validation study has confirmed that the CARING criteria may be used upon admission to estimate the risk of death at one year for inpatients in broad hospital settings.